Structural characterization of a human Fc fragment engineered for lack of effector functions
Vaheh Oganesyan, Changshou Gao, Lena Shirinian, Herren Wu, William F Dall'Acqua, Vaheh Oganesyan, Changshou Gao, Lena Shirinian, Herren Wu, William F Dall'Acqua
Abstract
The first three-dimensional structure of a human Fc fragment genetically engineered for the elimination of its ability to mediate antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity is reported. When introduced into the lower hinge and CH2 domain of human IgG1 molecules, the triple mutation L234F/L235E/P331S ('TM') causes a profound decrease in their binding to human CD64, CD32A, CD16 and C1q. Enzymatically produced Fc/TM fragment was crystallized and its structure was solved at a resolution of 2.3 A using molecular replacement. This study revealed that the three-dimensional structure of Fc/TM is very similar to those of other human Fc fragments in the experimentally visible region spanning residues 236-445. Thus, the dramatic broad-ranging effects of TM on IgG binding to several effector molecules cannot be explained in terms of major structural rearrangements in this portion of the Fc.
Figures
References
- Anderson, D. R., Grillo-Lopez, A., Varns, C., Chambers, K. S. & Hanna, N. (1997). Biochem. Soc. Trans.25, 705–708.
- Armour, K. L., van de Winkel, J. G., Williamson, L. M. & Clark, M. R. (2003). Mol. Immunol.40, 585–593.
- Canfield, S. M. & Morrison, S. L. (1991). J. Exp. Med.173, 1483–1491.
- Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002). Blood, 99, 754–758.
- Chappel, M. S., Isenman, D. E., Everett, M., Xu, Y. Y., Dorrington, K. J. & Klein, M. H. (1991). Proc. Natl Acad. Sci. USA, 88, 9036–9040.
- Collaborative Computational Project, Number 4 (1994). Acta Cryst. D50, 760–763.
- Deisenhofer, J. (1981). Biochemistry, 20, 2361–2370.
- Green, M. C., Murray, J. L. & Hortobagyi, G. N. (2000). Cancer Treat. Rev.26, 269–286.
- Hezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. & Parren, P. W. (2001). J. Virol.75, 12161–12168.
- Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G. & Mulkerrin, M. G. (2000). J. Immunol.164, 4178–4184.
- Jones, T. A., Zou, J.-Y., Cowan, S. W. & Kjeldgaard, M. (1991). Acta Cryst. A47, 110–119.
- Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S. & Foeller, C. (1991). Sequences of Proteins of Immunological Interest, 5th ed. Bethesda: NIH Publications.
- Kabsch, W. (1976). Acta Cryst. A32, 922–923.
- Krapp, S., Mimura, Y., Jefferis, R., Huber, R. & Sondermann, P. (2003). J. Mol. Biol.325, 979–989.
- Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. (1993). J. Appl. Cryst.26, 283–291.
- McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C. & Read, R. J. (2005). Acta Cryst. D61, 458–464.
- Matsumiya, S., Yamaguchi, Y., Saito, J., Nagano, M., Sasakawa, H., Otaki, S., Satoh, M., Shitara, K. & Kato, K. (2007). J. Mol. Biol.368, 767–779.
- Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997). Acta Cryst. D53, 240–255.
- Oganesyan, V., Damschroder, M. M., Leach, W., Wu, H. & Dall’Acqua, W. (2008). Mol. Immunol.45, 1872–1882.
- Otwinowski, Z. & Minor, W. (1997). Methods Enzymol.276, 307–326.
- Painter, J. & Merritt, E. A. (2006a). Acta Cryst. D62, 439–450.
- Painter, J. & Merritt, E. A. (2006b). J. Appl. Cryst.39, 109–111.
- Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. (2000). Nature (London), 406, 267–273.
- Tao, M. H., Smith, R. I. & Morrison, S. L. (1993). J. Exp. Med.178, 661–667.
- Weng, W. K. & Levy, R. (2003). J. Clin. Oncol.21, 3940–3947.
- Xu, D., Alegre, M. L., Varga, S. S., Rothermel, A. L., Collins, A. M., Pulito, V. L., Hanna, L. S., Dolan, K. P., Parren, P. W., Bluestone, J. A., Jolliffe, L. K. & Zivin, R. A. (2000). Cell. Immunol.200, 16–26.
Source: PubMed